Welcome to our dedicated page for ARTIVA BIOTHERAPEUTICS SEC filings (Ticker: ARTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artiva Biotherapeutics filings document its clinical-stage biotechnology business, Nasdaq-listed common stock and material-event reporting. Recent Form 8-K disclosures cover quarterly and annual financial results, Regulation FD updates on AlloNK® (AB-101) clinical data, and exhibits such as press releases and corporate presentations.
The filing record also describes governance and compensation matters, including board and officer appointments, employment arrangements, non-employee director compensation, inducement awards and an option-for-RSU exchange under the 2024 Equity Incentive Plan. Artiva’s disclosures identify AlloNK as an off-the-shelf NK cell therapy candidate used with anti-CD20 monoclonal antibodies in autoimmune-disease trials, alongside standard public-company capital-structure and securities information.
Artiva Biotherapeutics received an updated ownership disclosure from GC Corp, GC Cell Corporation and Yong‑Jun Huh following their participation in Artiva’s May 2026 underwritten offering. GC Corp bought 1,085,069 shares and GC Cell Corporation bought 347,222 shares of common stock at $11.52 per share.
After these purchases, GC Corp is reported as beneficially owning 5,999,703 shares, or 12.3% of Artiva’s common stock, and GC Cell Corporation 1,607,734 shares, or 3.3%, based on 48,588,198 shares outstanding. Yong‑Jun Huh may be deemed a beneficial owner of the shares held by GC Corp and GC Cell for Section 13(d) purposes but expressly disclaims beneficial ownership for other purposes.
GC Corp. and subsidiary GC Cell Corporation, both 10% owners of Artiva Biotherapeutics, Inc., bought a combined 1,432,291 shares of Artiva common stock in open‑market transactions. The purchases were made on May 11, 2026 at $11.52 per share.
After these transactions, GC Cell Corporation held 1,607,734 Artiva shares indirectly and GC Corp. held 4,391,969 shares directly. Footnotes explain that GC Corp. is a Korean holding company ultimately controlled by its board, whose members may be deemed to share voting and investment power but each disclaims beneficial ownership except for any pecuniary interest.
Artiva Biotherapeutics, Inc. senior vice president of research and development Heather Raymon reported an open-market sale of 3,095 shares of common stock at a weighted average price of $9.0078 per share. According to the company’s sell-to-cover policy, these shares were sold automatically to satisfy tax withholding on vested restricted stock units. After this transaction, Raymon directly holds 148,228 Artiva shares.
Artiva Biotherapeutics, Inc. senior vice president of research and development Heather Raymon reported an open-market sale of 3,095 shares of common stock at a weighted average price of $9.0078 per share. According to the company’s sell-to-cover policy, these shares were sold automatically to satisfy tax withholding on vested restricted stock units. After this transaction, Raymon directly holds 148,228 Artiva shares.
Artiva Biotherapeutics, Inc. reported that Chief Tech Operations Officer Christopher Horan sold 7,002 shares of common stock on May 19, 2026 at a weighted average price of $9.0078 per share. The price range for these sales was between $8.7421 and $9.0104.
According to the company’s sell-to-cover policy, these automatic sales were made solely to cover tax withholding obligations arising from the vesting and release of restricted stock units, and were not discretionary trades. After the transaction, Horan directly owned 293,450 shares of Artiva common stock.
Artiva Biotherapeutics, Inc. reported that Chief Tech Operations Officer Christopher Horan sold 7,002 shares of common stock on May 19, 2026 at a weighted average price of $9.0078 per share. The price range for these sales was between $8.7421 and $9.0104.
According to the company’s sell-to-cover policy, these automatic sales were made solely to cover tax withholding obligations arising from the vesting and release of restricted stock units, and were not discretionary trades. After the transaction, Horan directly owned 293,450 shares of Artiva common stock.
Artiva Biotherapeutics COO Jennifer Bush reported an automatic sale of 8,790 common shares to cover tax withholding on vested restricted stock units. The shares were sold in the open market at a weighted average price of $9.0078 per share, within a range of $8.7439 to $9.0104. After this sell-to-cover transaction under the company’s tax policy, she continues to hold 337,920 shares directly.
Artiva Biotherapeutics COO Jennifer Bush reported an automatic sale of 8,790 common shares to cover tax withholding on vested restricted stock units. The shares were sold in the open market at a weighted average price of $9.0078 per share, within a range of $8.7439 to $9.0104. After this sell-to-cover transaction under the company’s tax policy, she continues to hold 337,920 shares directly.
Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, sold 7,037 shares of common stock in an open-market transaction at a weighted average price of $9.0076 per share. The company explains these automatic sales were made solely to cover tax withholding obligations tied to vested restricted stock units. Following the sale, Banerjee directly holds 144,963 shares.
Artiva Biotherapeutics' Chief Medical Officer, Subhashis Banerjee, sold 7,037 shares of common stock in an open-market transaction at a weighted average price of $9.0076 per share. The company explains these automatic sales were made solely to cover tax withholding obligations tied to vested restricted stock units. Following the sale, Banerjee directly holds 144,963 shares.
Artiva Biotherapeutics, Inc. Chief Executive Officer Fred Aslan reported an open-market sale of 27,116 shares of common stock at a weighted average price of $9.0077 per share. After this transaction, he directly holds 1,535,082 shares.
The company has a “sell-to-cover” policy for tax withholding on vesting restricted stock units, and these shares were sold automatically to cover related tax obligations, not at Aslan’s discretion. Sale prices ranged between $8.7383 and $9.0104.
Artiva Biotherapeutics, Inc. Chief Executive Officer Fred Aslan reported an open-market sale of 27,116 shares of common stock at a weighted average price of $9.0077 per share. After this transaction, he directly holds 1,535,082 shares.
The company has a “sell-to-cover” policy for tax withholding on vesting restricted stock units, and these shares were sold automatically to cover related tax obligations, not at Aslan’s discretion. Sale prices ranged between $8.7383 and $9.0104.
Artiva Biotherapeutics President & Head of R&D Diego Miralles received new equity awards. He was granted 77,500 shares of common stock as restricted stock units and 232,500 employee stock options with an exercise price of $9.22 per share under the company’s 2025 Inducement Plan.
Following the grants, he directly holds 77,500 shares of common stock and 232,500 options. According to the award terms, 25% of the option shares vest on May 15, 2027, with the remaining shares vesting monthly over the next 36 months.
Artiva Biotherapeutics President & Head of R&D Diego Miralles received new equity awards. He was granted 77,500 shares of common stock as restricted stock units and 232,500 employee stock options with an exercise price of $9.22 per share under the company’s 2025 Inducement Plan.
Following the grants, he directly holds 77,500 shares of common stock and 232,500 options. According to the award terms, 25% of the option shares vest on May 15, 2027, with the remaining shares vesting monthly over the next 36 months.
Artiva Biotherapeutics announced several leadership changes and a new executive compensation package. On May 18, 2026, Diego Miralles, M.D. resigned from the Board and was appointed President and Head of Research and Development, reducing the Board size from eight to seven members. That same day, the company and Chief Financial Officer Thad Huston agreed to his separation, effective May 22, 2026; he will receive about $135,000 (three months of base salary) and up to nine months of COBRA health coverage under a separation agreement.
On the effective date, CEO Fred Aslan, M.D. was also appointed principal financial officer and principal accounting officer while remaining CEO and a director. Under an offer letter, Dr. Miralles will receive a $600,000 annual base salary, a discretionary annual bonus targeted at 45% of salary, options to purchase 232,500 shares, and 77,500 restricted stock units, all vesting over four years. The offer includes non–change-of-control and change-of-control severance protections that provide salary continuation, COBRA coverage, bonus eligibility and equity vesting acceleration if specified termination conditions are met.
Artiva Biotherapeutics announced several leadership changes and a new executive compensation package. On May 18, 2026, Diego Miralles, M.D. resigned from the Board and was appointed President and Head of Research and Development, reducing the Board size from eight to seven members. That same day, the company and Chief Financial Officer Thad Huston agreed to his separation, effective May 22, 2026; he will receive about $135,000 (three months of base salary) and up to nine months of COBRA health coverage under a separation agreement.
On the effective date, CEO Fred Aslan, M.D. was also appointed principal financial officer and principal accounting officer while remaining CEO and a director. Under an offer letter, Dr. Miralles will receive a $600,000 annual base salary, a discretionary annual bonus targeted at 45% of salary, options to purchase 232,500 shares, and 77,500 restricted stock units, all vesting over four years. The offer includes non–change-of-control and change-of-control severance protections that provide salary continuation, COBRA coverage, bonus eligibility and equity vesting acceleration if specified termination conditions are met.
ARTV reported a proposed sale of 3,500 shares of Common Stock via a Form 144 notice. The shares relate to Restricted Stock Units that vested on 05/15/2026 and are described as compensation for services rendered. The broker listed is Morgan Stanley Smith Barney LLC.